₹31.07
▲ +0.97 +3.22%
As of 29 Jul 2026 · delayed
BSE Listed
Shukra Pharmaceuticals Limited (524632)
Volume: 1,93,196Avg Vol 1W: 1,73,487Avg Vol 1M: 3,08,19752W Range:₹17.06₹65.26
Key Ratios
Checked 11h agoMarket Cap₹1,318 Cr
Current Price₹31.07
Previous Close₹30.1
High / Low (52w)₹65.26 / ₹17.06
Volume1,93,196
Avg Vol (1W)1,73,487
Avg Vol (1M)3,08,197
Stock P/E60.2
Book Value₹2.05
Dividend Yield3%
ROE24.55%
ROA18.78%
Revenue (TTM)—
Revenue Growth—
Profit Margin38.88%
Total Debt—
Shares Outstanding44 Cr
Face Value—
EPS (TTM)₹0.5
P/B14.67
Debt / Equity0.06
50 DMA₹30.96
200 DMA₹38.44
Day change+3.22%
Price Chart
₹31.07▲ 50.10% · 1Y
2025-07-302026-07-29
20-day avg volume: 3.3L shares
Pros
- Healthy return on equity of 24.6%.
- Pays a dividend yield of 3.0%.
- Company is almost debt-free.
Cons
- Revenue fell 84% YoY.
- Company is loss-making at the latest annual result.
- Stock trades at a high P/E of 60.
Quarterly Results
| Metric | Dec 2024 | Mar 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | ₹11 Cr | ₹13 Cr | ₹6 Cr | ₹39 Cr | ₹6 Cr |
| EBITDA | ₹4 Cr | ₹8 Cr | ₹0 Cr | ₹27 Cr | ₹1 Cr |
| Net Profit | ₹3 Cr | ₹5 Cr | ₹2 Cr | ₹20 Cr | ₹-2 Cr |
| EPS | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6 Cr | ₹11 Cr | ₹37 Cr | ₹13 Cr | ₹5 Cr | ₹6 Cr | ₹39 Cr | ₹6 Cr |
| EBITDA | ₹1 Cr | ₹4 Cr | ₹14 Cr | ₹8 Cr | ₹2 Cr | ₹0 Cr | ₹27 Cr | ₹1 Cr |
| Net Profit | ₹1 Cr | ₹3 Cr | ₹10 Cr | ₹5 Cr | ₹1 Cr | ₹2 Cr | ₹20 Cr | ₹-2 Cr |
| EPS | — | — | 0.22 | — | — | — | — | — |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹24 Cr | ₹28 Cr | ₹34 Cr | ₹36 Cr | ₹35 Cr | ₹75 Cr | ₹78 Cr | ₹87 Cr |
| Total Liabilities | ₹9 Cr | ₹13 Cr | ₹18 Cr | ₹20 Cr | ₹19 Cr | ₹50 Cr | ₹20 Cr | ₹24 Cr |
| Equity | ₹15 Cr | ₹15 Cr | ₹15 Cr | ₹16 Cr | ₹16 Cr | ₹25 Cr | ₹58 Cr | ₹63 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Operating | ₹1 Cr | ₹8 Cr | ₹3 Cr | ₹-5 Cr | ₹12 Cr |
| Investing | ₹-2 Cr | ₹-2 Cr | ₹-4 Cr | ₹-1 Cr | ₹-1 Cr |
| Financing | ₹2 Cr | ₹-7 Cr | ₹5 Cr | ₹12 Cr | ₹-5 Cr |
| Free Cash Flow | ₹1 Cr | ₹8 Cr | ₹3 Cr | ₹-5 Cr | ₹12 Cr |
Shareholding
Promoter 50.96% Institutions 0.12% Public 48.92%
Efficiency & Working Capital
ROCE31.5%
Interest Coverage23.6
Dividend Payout—
Debtor Days98 d
Inventory Days111 d
Payable Days103 d
Cash Conversion Cycle106 d
Working Capital Days210 d
Shareholding Details
As of 2026-06-30
Promoter51%
FII0%
DII0.1%
Institutions0.1%
Public48.9%
Promoter Pledge0%
No. of Shareholders28,384
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 50.9% | 51% | 51% | 51% | 51% | 51% | 51% | 51% | 51% | 51% | 51% | 51% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| Public | 49% | 48.9% | 48.9% | 48.9% | 48.9% | 48.9% | 48.9% | 48.9% | 48.9% | 48.9% | 48.9% | 48.9% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 9,747 | 10,963 | 12,974 | 14,989 | 16,321 | 17,844 | 18,231 | 20,337 | 21,441 | 25,649 | 27,173 | 28,384 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Renuka Yogesh Parikh | Public Shareholding | 19.2% | 8.40 Cr |
| Yogesh Biharilal Parikh | Public Shareholding | 19.1% | 8.38 Cr |
| Anar Project Private Limited | Shareholding of Promoter and Promoter Group | 18.8% | 8.22 Cr |
| Parshva Texchem India Private Ltd. | Shareholding of Promoter and Promoter Group | 17.2% | 7.52 Cr |
| Navkar Surgical Gujarat | Shareholding of Promoter and Promoter Group | 11.8% | 5.16 Cr |
| Anar Jayeshbhai Patel | Shareholding of Promoter and Promoter Group | 1% | 43,60,000 |
| Dakshesh Rameshchandra Shah | Shareholding of Promoter and Promoter Group | 1% | 43,60,000 |
| Sujay Jyotindra Mehta | Shareholding of Promoter and Promoter Group | 0.7% | 31,20,000 |
| Payal Sujay Mehta | Shareholding of Promoter and Promoter Group | 0.5% | 22,80,000 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Dakshesh Shah | Chairman / Executive Director / Managing Director | 2025 |
| Payal Mehta | Executive Director | 2025 |
| Dhruvin Shah | E D & Wholetime Director | 2025 |
| Sanskruti Patel | E D & Wholetime Director | 2025 |
| Pinki Nirmal Sagar | Independent Non Exe. Director | 2025 |
| Sonal Deepalbhai Gandhi | Independent Non Exe. Director | 2025 |
| Sarjeevan Singh | Independent Non Exe. Director | 2025 |
| Jitendra shah | Independent Non Exe. Director | 2025 |
| Anar Jayesh Patel | Executive Director / Whole Time Director / CFO | 2025 |
| SHITAL DAKSHESH SHAH | E D & Wholetime Director | 2025 |
| Ritu Kapoor | Independent Non Exe. Director | 2025 |
| Shivkant Dhakad | Company Secretary / Compliance Officer | 2025 |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹1 | 49 | 44 | 44 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| dividend | 2025-09-18 | ₹0.01 (1%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 4 | 0 | 4 |
| 2025 | 0 | 0 | 0 | 3 | 0 | 3 |
| 2025 | 0 | 0 | 0 | 1 | 0 | 1 |
Company Information
🌐 www.shukrapharmaceuticals.com ↗
📍 3 rd Floor Dev House, Opp WIAA Office Judges Bungalo, Ahmedabad, Gujarat, 380054
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search